These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1035 related items for PubMed ID: 16954357

  • 1. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J, Robertus K.
    Ann Intern Med; 2006 Sep 05; 145(5):317-25. PubMed ID: 16954357
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
    Sanford M, Keating GM.
    Drugs Aging; 2010 Feb 01; 27(2):159-76. PubMed ID: 20104941
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Rothberg MB, Virapongse A, Smith KJ.
    Clin Infect Dis; 2007 May 15; 44(10):1280-8. PubMed ID: 17443464
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM, Brisson M, Levin MJ.
    Vaccine; 2007 Nov 28; 25(49):8326-37. PubMed ID: 17980938
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
    Le P, Rothberg MB.
    Ann Intern Med; 2015 Oct 06; 163(7):489-97. PubMed ID: 26344036
    [Abstract] [Full Text] [Related]

  • 7. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, Varghese L, Curran D.
    Appl Health Econ Health Policy; 2019 Oct 06; 17(5):723-732. PubMed ID: 31250218
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M.
    Hum Vaccin Immunother; 2021 Dec 02; 17(12):5296-5303. PubMed ID: 34905463
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
    Hoshi SL, Kondo M, Okubo I.
    Vaccine; 2017 May 31; 35(24):3264-3271. PubMed ID: 28479176
    [Abstract] [Full Text] [Related]

  • 11. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K, Weinberg JM.
    J Drugs Dermatol; 2006 Oct 31; 5(9):863-6. PubMed ID: 17039651
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.
    Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, Bénard É, Brisson M.
    CMAJ; 2019 Aug 26; 191(34):E932-E939. PubMed ID: 31451524
    [Abstract] [Full Text] [Related]

  • 13. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
    Annemans L, Bresse X, Gobbo C, Papageorgiou M.
    J Med Econ; 2010 Aug 26; 13(3):537-51. PubMed ID: 20707768
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of herpes zoster vaccine in Canada.
    Najafzadeh M, Marra CA, Galanis E, Patrick DM.
    Pharmacoeconomics; 2009 Aug 26; 27(12):991-1004. PubMed ID: 19908924
    [Abstract] [Full Text] [Related]

  • 15. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.
    Hum Vaccin; 2008 Aug 26; 4(3):238-45. PubMed ID: 18382137
    [Abstract] [Full Text] [Related]

  • 16. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1495-1504. PubMed ID: 28481678
    [Abstract] [Full Text] [Related]

  • 17. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.
    BMC Health Serv Res; 2013 Sep 26; 13():359. PubMed ID: 24070414
    [Abstract] [Full Text] [Related]

  • 18. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF, Lewin B, Hales CM, Sy LS, Harpaz R, Bialek S, Luo Y, Jacobsen SJ, Reddy K, Huang PY, Zhang J, Anand S, Bauer EM, Chang J, Tartof SY.
    J Infect Dis; 2015 Oct 15; 212(8):1222-31. PubMed ID: 26038400
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N.
    Hum Vaccin Immunother; 2015 Oct 15; 11(4):884-96. PubMed ID: 25933182
    [Abstract] [Full Text] [Related]

  • 20. A systematic review of the cost effectiveness of herpes zoster vaccination.
    Szucs TD, Pfeil AM.
    Pharmacoeconomics; 2013 Feb 15; 31(2):125-36. PubMed ID: 23335045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.